According to a recent LinkedIn post from Neuromod Devices Ltd, company representatives Hans Zwart and Thomas Borgaa plan to represent its Lenire tinnitus treatment at the DSOHH meeting in Nyborg Strand, Denmark, on April 16–17. The post indicates they will be available at Booth 23 to discuss clinical outcomes, patient experiences, and potential future collaborations around bimodal neuromodulation for tinnitus care.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Neuromod Devices is actively engaging with audiology and ENT professionals, which may support broader clinical adoption of Lenire in Scandinavian and wider European markets. Increased visibility among specialists at such meetings could contribute to referral growth, partnership opportunities, and, over time, revenue expansion if clinical interest converts into greater use of the company’s neuromodulation solution.